News 07.01.2018 Molecular Partners AG announced that Allergan has exercised two options to develop and commercialize DARPin® product candidates from its 2012 discovery alliance agreement with Molecular Partners. Upon receipt of approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, Molecular Partners will grant Allergan an exclusive license to the...
News 09.11.2017 Neurimmune, a global leader in the discovery and development of human-derived monoclonal antibodies, today announced that it has entered into a collaboration with Ono Pharmaceutical Co., Ltd. focused on the development of human antibodies against a novel therapeutic target for neurodegenerative diseases. Under the terms of the collaboration agreement Neurimmune...
News 24.10.2017 Neurimmune announced today that it has raised $150 million to fund its growth strategy. The financing will accelerate the development of Neurimmune's human antibody pipeline through clinical proof of concept. Neurimmune receives a one-time $150 million payment from its collaboration partner Biogen in exchange for a 15% reduction in the previously...
News 30.08.2017 Biogen (NASDAQ: BIIB) announced results from a recently conducted analysis of the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, the company’s investigational treatment for early Alzheimer’s disease. The updated analyses include data from the placebo-controlled period and LTE for patients treated with aducanumab up to 24...
News 28.08.2017 Virometix today announced that it has raised CHF 1.2 million from new shareholders in an extension to its recent Series A financing round. The additional funds will be used to further speed up development of its vaccine candidates for RSV and cancer immunotherapy. Furthermore, the company announced the appointment of...